The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer
What is the purpose of this trial?
This is a phase 2 study to investigate NC318 alone or in combination with Pembrolizumab in patients with advanced non-small cell lung cancer.
- Trial withYale Cancer Center
- Start Date12/21/2021
- End Date06/01/2025
- Last Updated01/04/2022
- Study HIC#2000028206